Loading…
Reported covered position: Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
IRA WATCHDOG via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Source: Senate LDA
| IRA WATCHDOG |
| 7 |
| 2025–2026 |
| NOVARTIS | 7 | 2025–2026 |
| PRELUDE CORPORATION (PRELUDEDX) | 6 | 2025–2026 |
| AVALYN PHARMA INC. | 5 | 2025–2026 |
| DUKE UNIVERSITY HEALTH SYSTEM | 5 | 2025 |
| REGENXBIO INC. | 5 | 2025–2026 |
| WE WORK FOR HEALTH | 5 | 2024–2025 |
| ELI LILLY & COMPANY | 4 | 2024 |
| AIDOC, INC. | 3 | 2025–2026 |
| NEXUS PHARMACEUTICALS, LLC | 3 | 2024 |
| Vertanical GmbH | 3 | 2023 |
| CALIFORNIA APARTMENT ASSOCIATION | 2 | 2025 |
| CURRAX PHARMACEUTICALS LLC | 2 | 2025 |
| PATHAI | 2 | 2024 |
| RAI SERVICES COMPANY | 2 | 2023 |
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 8646, Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 8646, Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BIONJ, INC. · Firm: DLA PIPER LLP (US)
Public policy matters impacting the life sciences industry. H.R. 1, One Big Beautiful Bill Act, tax and healthcare provisions.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BIONJ, INC. · Firm: DLA PIPER LLP (US)
Public policy matters impacting the life sciences industry. H.R. 1, One Big Beautiful Bill Act, tax and healthcare provisions.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BIOGEN, INC. · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. S. 4638, National Defense Authorization Act for FY2025, provisions regarding medical device innovation.
VALID Act of 2023
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. S. 4638, National Defense Authorization Act for FY2025, provisions regarding medical device innovation.
VALID Act of 2023
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023.
VALID Act of 2023
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
VALID Act of 2023
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
National Defense Authorization Act for Fiscal Year 2025
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. S. 4638, National Defense Authorization Act for FY2025, provisions regarding medical device innovation.
VALID Act of 2023
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023.
Medicare policies.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Trade-related public policy around tariffs and intellectual property.
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Center for Tobacco products oversight. FDA oversight. H.R. 8646, Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BIONJ, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Public policy matters impacting the life sciences industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies related to Medicare reimbursement for cancer diagnostics.
Improved patient access to cancer screening diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Medicare policies.
National security issues related to pharmaceutical industry, including supply chain.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
NOVARTIS via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Tariffs and biotechnology issues related to Treasury and competition with China.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Trade-related public policy around tariffs and intellectual property.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies related to Medicare reimbursement for cancer diagnostics.
Improved patient access to cancer screening diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IRA WATCHDOG via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Center for Tobacco products oversight. FDA oversight. H.R. 8646, Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BIONJ, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Public policy matters impacting the life sciences industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRA WATCHDOG via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Tariffs.
Tax reform and tax policy.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Trade policies and agreements, including IP protections, and administrative tariff actions.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
AIDOC, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Government systems for AI integration. Regulation of AI medical technology.
Government systems for AI integration. Medicare coverage for AI technology.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Improved patient access to cancer screening diagnostics.
Policies related to Medicare reimbursement for cancer diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Center for Tobacco products oversight. FDA oversight. Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BIONJ, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Public policy matters impacting the life sciences industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIDOC, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Government systems for AI integration.
Government systems for AI integration.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
AIDOC, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Government systems for AI integration.
Government systems for AI integration.
IRA WATCHDOG via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
NOVARTIS via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Tax reform and tax policy.
Tariffs.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
BIONJ, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Public policy matters impacting the life sciences industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Improved patient access to cancer screening diagnostics.
Policies related to Medicare reimbursement for cancer diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA APARTMENT ASSOCIATION via DLA PIPER LLP (US)
2025 · fourth_quarter · 4T
Issues regarding the Veterans Health Care Act of 1992.
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
REGENXBIO INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Issues related to rare disease.
Issues related to rare disease.
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Issues related to rare disease.
Issues related to rare disease.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · third_quarter · Q3
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
IRA WATCHDOG via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
NOVARTIS via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Tax reform and tax policy.
Tariffs.
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CALIFORNIA APARTMENT ASSOCIATION via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues regarding the Veterans Health Care Act of 1992.
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Improved patient access to cancer screening diagnostics.
Policies related to Medicare reimbursement for cancer diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIONJ, INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Public policy matters impacting the life sciences industry. H.R. 1, One Big Beautiful Bill Act, tax and healthcare provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2025 · third_quarter · RR
Policies regarding Medicare reimbursement for cancer diagnostic.
Policies regarding Medicare reimbursement for cancer diagnostic.
IRA WATCHDOG via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRA WATCHDOG via DLA PIPER LLP (US)
2025 · second_quarter · RR
Impact of Medicare Drug Price Negotiation Program on patients.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2025 · second_quarter · Q2
FDA oversight. FY2026 appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIONJ, INC. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Public policy matters impacting the life sciences industry. H.R. 1, One Big Beautiful Bill Act, tax and healthcare provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing supply chain. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Drug pricing. Supply chain issues and gene therapy. Policies related to value based arrangements and implementation of Inflation Reduction Act of 2022.
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · second_quarter · RR
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
BIONJ, INC. via DLA PIPER LLP (US)
2025 · second_quarter · RR
Public policy matters impacting the life sciences industry.
NOVARTIS via DLA PIPER LLP (US)
2025 · second_quarter · RR
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · second_quarter · RR
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2025 · second_quarter · RR
FDA regulation and enforcement policies.
FDA regulation and enforcement policies.
FDA regulation and enforcement policies.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via DLA PIPER LLP (US)
2025 · first_quarter · 1T
Pharmacy benefit manager reform, intellectual property issues, and other drug pricing related issues.
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Legislative and regulatory policies and proposals related to obesity treatment. Article 20 pharmacovigilance proceedings before the European Commission.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · first_quarter · RR
Policies and proposals related to coverage and reimbursement, federal government research funding.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · first_quarter · RR
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
ELI LILLY & COMPANY via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Pharmaceutical supply chain security and resiliency.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. S. 4638, National Defense Authorization Act for FY2025, provisions regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Pharmacy benefit manager reform, intellectual property issues, and other drug pricing related issues.
Filing targets: SENATE
ELI LILLY & COMPANY via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Pharmaceutical supply chain security and resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEXUS PHARMACEUTICALS, LLC via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Advocating for regulatory enforcement of pharmacy compounders manufacturing approved drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Pharmacy benefit manager reform, intellectual property issues, and other drug pricing related issues.
Filing targets: SENATE
WE WORK FOR HEALTH via DLA PIPER LLP (US)
2024 · second_quarter · Q2
Pharmacy benefit manager reform, intellectual property issues, and other drug pricing related issues.
Filing targets: SENATE
NEXUS PHARMACEUTICALS, LLC via DLA PIPER LLP (US)
2024 · second_quarter · Q2
Advocating for regulatory enforcement of pharmacy compounders manufacturing approved drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via DLA PIPER LLP (US)
2024 · second_quarter · Q2
Pharmaceutical supply chain security and resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2024 · second_quarter · Q2
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via DLA PIPER LLP (US)
2024 · second_quarter · RR
Pharmacy benefit manager reform, intellectual property issues, and other drug pricing related issues.
NEXUS PHARMACEUTICALS, LLC via DLA PIPER LLP (US)
2024 · second_quarter · RR
Advocating for regulatory enforcement of pharmacy compounders manufacturing approved drug products.
ELI LILLY & COMPANY via DLA PIPER LLP (US)
2024 · second_quarter · RR
Pharmaceutical supply chain security and resiliency.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform.
Trade-related public policy around tariffs and intellectual property.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to rare disease and treatment. Pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues related to tax reform.
Trade-related public policy around tariffs and intellectual property.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Tax reform and tax policy.
Tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.